Eric Aguiar
Director · BridgeBio Pharma, Inc.
- 2025
- Jun 24, 2026
- 4
Summary
Latest filing:
Eric Aguiar is Director of BridgeBio Pharma, Inc. (BBIO). 4 SEC Form 4 filings on record going back to 2025, most recently on 24 June 2026.
Recent transactions
2The latest 2 SEC Form 4 transactions reported by Eric Aguiar.
Trading pattern
InsiderAlpha's records for Eric Aguiar go back to 2025: 4 primary Form 4 filings, an average of 2.0 per year. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Eric Aguiar files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Neil Kumar - $45.20M in BBIO purchases and sales in the last 12 months
- Jennifer E. Cook - $21.92M in BBIO purchases and sales in the last 12 months
- Andrew Lo - $6.32M in BBIO purchases and sales in the last 12 months
- Andrea Ellis - $5.65M in BBIO purchases and sales in the last 12 months
- Hannah Valantine - $4.37M in BBIO purchases and sales in the last 12 months
- Ronald J. Daniels - $3.89M in BBIO purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Eric Aguiar?
Eric Aguiar is a corporate insider, tracked as Director of BridgeBio Pharma, Inc. (BBIO). InsiderAlpha holds 4 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Eric Aguiar last file a Form 4?
The most recent primary Form 4 on record is dated 24 June 2026, one of 4 filings going back to 2025.